Investment - Unibest Industrial Co., Ltd.

:
All

Product Name

Product Keyword

Product Model

Product Summary

Product Description

Multi Field Search
About

Our History

Management Team

Consultant

Our Partner

ESG

Services

CDMO/CRO

NewCo & License Out

DS and DP Registration

Investment

Product Support

Human Pharma

Human Pharma Intermediates

Human Pharma API

Lab Reagents

Fluorination and Chlorination

Cinchona Alkaloids

Biopharm R&D

Carbon Source - Cell Culture

Nitrogen Source - Cell Culture

Vitamin - Cell Culture

Nutrients - Cell Culture

Other Supplements- Culture Media

Antibiotics - Culture Media

Cytokines

Microorganism Culture Media Supplements

Oligonucleotides

Nucleosides - Oligonucleotides

Nucleoside Derivatives - Oligonucleotides

Phosphoramidites - Oligonucleotides

Delivery System - Oligonucleotides

Liposome Components

Kinase

Why Us

Quality Control

Cost Saving

R & D

News & Blogs

Pharmaceutical Market Analysis

Unibest Drug Briefing

Unibest Drug IP Watch
CONTACT

Investment

At Unibest Industrial, our investment strategy is designed to drive innovation and growth in the pharmaceutical and biotech sectors. We focus on identifying and supporting promising drug development projects, emerging technologies, and strategic partnerships that have the potential to transform healthcare. Our investment portfolio reflects our commitment to fostering innovation, improving patient outcomes, and creating long-term value for our partners and stakeholders.

1

Early-Stage Biotech

We actively seek investment opportunities in early-stage biotech companies with innovative drug candidates or cutting-edge technologies. Our goal is to provide strategic support and funding to help these companies navigate the challenging early stages of drug development and bring their products closer to market.
2

Emerging Technologies

Our investment strategy includes backing emerging technologies that have the potential to revolutionize the pharmaceutical industry. This includes advancements in AI-driven drug discovery, green chemistry, and continuous manufacturing processes. By investing in these technologies, we aim to drive sustainable and efficient drug development practices.
3

Strategic Partnerships

We also focus on forming strategic partnerships with established pharmaceutical companies and emerging biotechs. These partnerships allow us to leverage our expertise in drug development, regulatory compliance, and market access to accelerate the commercialization of innovative therapies.

Successful Investments

Over the past decade, we have participated in over 10 investments, with 14 drugs successfully launched in the market. Our portfolio includes collaborations with leading global pharmaceutical companies and innovative biotechs, driving the development of next-generation therapies.